NewsRoom Articles - Page 149 of 202

ThursdayMay 13, 2021 12:05 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders

Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia The company is also developing a clinical trial to address the needs of fibromyalgia patients who often rely on opioids to relieve their symptoms Tryp has announced two new collaborations for oversight of the drug trials this month; consultants with Fluence and Clinlogix will help to ensure the quality of the tests Bioscience pharmaceutical company Tryp Therapeutics (CSE:…

ThursdayMay 13, 2021 11:16 am

Fasting Reduces Blood Pressure, Restructures Gut Microbiome, Study Finds

A study conducted by researchers from Baylor College of Medicine has found that intermittent fasting (“IF”) has the potential to decrease hypertension by restructuring gut microbiome. Hypertension increases an individual’s risk for getting a stroke or cardiovascular ailments, which are the major causes of death within the United States. The objective of the team of researchers who conducted the study was to learn more about hypertension and, more specifically, about the evidence that suggested that blood pressure could increase if gut microbiota is disrupted in a process called gut dysbiosis. The team included Baylor professor of anesthesiology Dr. David Durgan,…

WednesdayMay 12, 2021 11:36 am

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) on Schedule for Completion in 2022

Imagin Medical’s contract manufacturer, Lighthouse Imaging, has developed a program focused on refining the i/Blue System’s design for manufacturing Lighthouse’s manufacturing process will ensure that regulatory standards are followed while maintaining optimal performance and staying within targeted costs Imagin is currently focusing on using the i/Blue system for bladder cancer visualization with plans to extend the use of the technology to other procedures in the future Imagin Medical (CSE: IME) (OTCQB: IMEXF) is on track to complete its patented i/Blue Imaging System(TM) in 2022. The innovative technology leverages proprietary light sensors and optics to improve the accuracy and efficiency of…

WednesdayMay 12, 2021 11:16 am

Healthy Extracts Inc. (HYEX) Announces Association Of Dr. Kahn With The Healthy Extracts Inc. Medical Board

Healthy Extracts Inc. announces the addition of Dr. Joel Kahn, M.D., a world-renowned, triple board-certified cardiology specialist to its medical board Dr. Kahn has personally conducted clinical studies that confirm the benefits of Citrus Bergamot SuperFruit(TM) for cardiovascular health Citrus Bergamot SuperFruit(TM), the main ingredient in BergametNA’s product line, is the super fruit alternative to prescribed cholesterol medications Healthy Extracts (OTCQB: HYEX), through its developing and acquiring complementary companies, is engaged in manufacturing plant-based formulations dedicated to heart and Brain health. With its focus towards strengthening its position in the multibillion-dollar nutraceuticals market, the company has already launched its science-based BergaMet North…

WednesdayMay 12, 2021 11:14 am

New Experimental Drug Reverses Crucial Alzheimer’s Symptoms

Scientists from the Albert Einstein College of Medicine have developed an experimental medication that reverses the major symptoms of Alzheimer’s disease. The researchers, who used mice for their research, found that the medication revitalized a cellular cleaning mechanism that eliminates unwanted proteins by recycling and digesting them. The research was reported in the “Cell” journal. Ana Maria Cuervo, a professor and a study leader, explained that while discoveries in mice didn’t always play out the same way in human beings, the researchers were encouraged to learn that the cell-cleaning process that they had observed in mice also occurred in patients…

TuesdayMay 11, 2021 2:36 pm

Brain Scientific Inc. (BRSF) Releases 2020 Financial, Business Results

BRSF made strides on operations front to improve lead times, quality control Company experienced revenue growth, increase in assets and R&D Brain Scientific has identified that only 30% of U.S. hospitals have equipment for routine EEGs due to cost and space constraints Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, announced it has filed its annual report for the fiscal year that ended Dec. 31, 2020 (https://ibn.fm/GCazt). The company reported key business highlights and substantial growth as well as outlined milestones expected to be completed over the next two years. “In 2020, Brain Scientific made good progress toward our vision of…

TuesdayMay 11, 2021 2:26 pm

United Medical Equipment Business Solutions Network Inc. Provides Patient Care and Education in One Convenient App

Simple design enables consumers to prevent medication errors Offers 12 different functionalities with the newest addition of GoodRX Now offering up to 85% discount on most medications at over 70,000 pharmacies Across the United States. Powered by GoodRX Download the APP now and not only manage your medication but save money every time you walk into your local Pharmacy by having your coupons ready United Medical Equipment Business Solutions Network ("UME") is in the business of helping families with medical resources, supplies and providing a network of reliable solutions. One of these solutions is the Medication Management App, developed to…

TuesdayMay 11, 2021 2:06 pm

Predictive Oncology’s (NASDAQ: POAI) C-Level Leaders Provide Company, Operations Update on New Podcast

Bell2Bell podcast features company CEO, CFO, CTO of Helomics subsidiary POAI is “in probably the best situation we’ve been in since the existence of the company,” reports CFO Company anticipates revenue from its unique PeDAL platform Three Predictive Oncology (NASDAQ: POAI) executives were featured guests on a recent Bell2Bell podcast (https://ibn.fm/DumLs). Newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, shared updates regarding POAI’s financial footing, current operations and goals for 2021 during the podcast, which delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Named Predictive…

TuesdayMay 11, 2021 10:58 am

Team of German Researchers Looks into Superspreaders Phenomenon

Researchers from the Otto von Guericke University Magdeburg are currently examining the rise and spread of aerosols using artificially manufactured suspended particles and tissue cultivations. The researchers, who hail from the departments of process engineering, biomedical sciences and physics, aim to discover why the “superspreader” phenomenon exists. The group of scientists will be investigating how virus particles in humans are packed into the infectious air bubbles and which processes allow these particles to stick to the airways of other individuals where they then pop, causing infection. The researchers from the process engineering department will be designing simulation models to help…

MondayMay 10, 2021 2:26 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) on Track to Begin Potentially Pivotal Phase 2 GBM Trial This Quarter for Berubicin

During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%) Additional research to be conducted by sublicensee partner WPD Pharmaceuticals, Inc. in Poland, including the first-ever pediatric trial The glioblastoma multiforme (“GBM”) treatment market is expected to reach $1.4 billion by 2027 CNS Pharma positioning to secure a leading role in treating GBM A potentially pivotal Phase 2 trial is on track to commence during Q2 2021 by CNS Pharmaceuticals (NASDAQ: CNSP). This trial is currently…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders

Fasting Reduces Blood Pressure, Restructures Gut Microbiome, Study Finds

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) on Schedule for Completion in 2022

Healthy Extracts Inc. (HYEX) Announces Association Of Dr. Kahn With The Healthy Extracts Inc. Medical Board

New Experimental Drug Reverses Crucial Alzheimer’s Symptoms

Brain Scientific Inc. (BRSF) Releases 2020 Financial, Business Results

United Medical Equipment Business Solutions Network Inc. Provides Patient Care and Education in One Convenient App

Predictive Oncology’s (NASDAQ: POAI) C-Level Leaders Provide Company, Operations Update on New Podcast

Team of German Researchers Looks into Superspreaders Phenomenon

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) on Track to Begin Potentially Pivotal Phase 2 GBM Trial This Quarter for Berubicin

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search